Prediction of Sustained Virological Response to Telaprevir-Based Triple Therapy Using Viral Response within 2 Weeks
Table 6
Comparison of pretreatment factors between patients with and without 2-week virological response.
Factors
Week 2 response (≥4.56-log reduction) ( = 21)
Non-week-2-response (<4.56-log reduction) ( = 12)
Age (years)
58
62
0.618
Sex (male/female)
13/8
5/7
0.300
Height (cm)
162.8
158.3
0.291
Weight (kg)
65.8
57.5
0.175
BMI
24.7
22.0
0.593
Baseline HCV-RNA (LogIU/mL; TaqMan)
6.8
6.2
0.013
Baseline HCV-RNA (LogIU/mL; AccuGene)
6.2
5.5
0.005
Baseline HCV core Ag (fmol/L)
6134.9
1485.3
0.003
No response to prior PEG-IFN and ribavirin
1
3
0.125
Fatty liver
6
0
0.065
Cirrhosis
7
8
0.083
Diabetes mellitus
3
2
1.000
IL28B (major/minor)
15/6
6/6
0.274
Core 70 (wild/mutant)
12/8
6/6
0.718
Core 91 (wild/mutant)
15/5
8/4
0.696
WBC (/mm3)
5160
4435
0.175
Hb (g/dL)
14.8
14.1
0.022
Platelets (/mm3)
16.7
14.8
0.345
ALT (IU/L)
51.0
43.5
0.927
γ-GT (IU/L)
34.0
38.0
0.868
Type VI collagen 7S (ng/mL)
4.8
4.8
0.811
Hyaluronic acid (ng/mL)
94.0
105.2
0.671
AFP (ng/mL)
4.5
6.7
0.811
Reduced dose regimen
15
12
0.065
Values are expressed as the median. BMI, body mass index; HCV, hepatitis C virus; Ag, antigen; IL, interleukin; WBC, white blood cells; Hb, hemoglobin; ALT, alanine aminotransferase; γ-GT, γ-glutamyl transferase; AFP, alpha-fetoprotein.